What Is Driving the New Fair Value Estimate for Exelixis? The fair value estimate for Exelixis has moved from US$45.61 to ...

Natera submits premarket approval to US FDA for Signatera CDx for detection of MRD in patients with muscle-invasive bladder cancer: Austin, Texas Wednesday, February 4, 2026, 18:0 ...

The test showed sensitivity of nearly 60 percent in the MRD window with specificity of 100 percent in patients who did not receive adjuvant chemotherapy.

NTRA submits FDA PMA for Signatera CDx, aiming to guide bladder cancer treatment with MRD testing after positive phase 3 ...

Natera, Inc. , a global leader in cell-free DNA and precision medicine, today announced the submission of its premarket approval (PMA) to the U.S. Food and Drug Administration (FDA) for Signateratm ...

NEW YORK – The minimal residual disease testing market continued to grow in 2025 as the biomarker based on the detection and analysis of circulating tumor DNA becomes increasingly clinically validated ...

Stage 3 colorectal cancer patients with MRD benefit from Celebrex addition to chemotherapy, showing a 40% risk reduction in death for Signatera-positive patients. Celebrex improved disease-free and ...

Natera Inc. (NASDAQ: NTRA) on Wednesday revealed initial translational research results from the international randomized Phase 3 PALLAS study. Data were presented at the San Antonio Breast Cancer ...

Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, together with Alliance Foundation Trials, LLC (AFT) and the Austrian Breast and Colorectal Cancer Study Group ...

AUSTIN, Texas--(BUSINESS WIRE)-- Natera, Inc. (NTRA), a global leader in cell-free DNA and precision medicine, together with Alliance Foundation Trials, LLC (AFT) and the Austrian Breast and ...

The health and medicine honorees for 2025 reflect the wide-ranging efforts of health tech companies to develop better ways to predict, detect, and treat problems earlier and more conveniently. They ...